Autologous CAR123 T lymphocytes cell tharapy(Institute of Hematology and Blood Transfusion, Czech Republic)

N/A

Report date: 2025/01/13 20:00:48

Base Information

Drug NameAutologous CAR123 T lymphocytes cell tharapy(Institute of Hematology and Blood Transfusion, Czech Republic)
Drug Alias NameAnti-CD123 Chimeric Antigen Receptor (CAR) T-Cells tharapy(Institute of Hematology and Blood Transfusion, Czech Republic)CART123 tharapy(Institute of Hematology and Blood Transfusion, Czech Republic)CAR123 T Cells tharapy(Institute of Hematology and Blood Transfusion, Czech Republic)
ClassificationCell and gene therapy > Cell therapy > Immune system cell therapy > Lymphocytes therapy > T-lymphocyte cell therapy > Chimeric antigen receptor T cell therapy
Mechanisms of ActionT lymphocyte replacementsAnti-CD123
TargetsInterleukin-3 receptor subunit alpha
Therapy Area/IndicationsBlastic Plasmacytoid Dendritic Cell NeoplasmMyelodysplastic SyndromesLeukemia, Myeloid, Acute +[4] 
Global Approved IndicationsN/A
Approved Indications in ChinaN/A
Original Approved Country/TerritoryN/A
Original Approved DateN/A
Country/TerritoryCzechia
CombinationsNo
Global Highest StatusPhase 1 Clinical
Highest Status in ChinaN/A
Originator CompaniesInstitute of Hematology and Blood Transfusion, Czech Republic
China Registration ClassN/A

Develop Information

Active CompaniesInstitute of Hematology and Blood Transfusion, Czech Republic
Inactive CompaniesN/A
Active IndicationsBlastic Plasmacytoid Dendritic Cell NeoplasmMyelodysplastic SyndromesLeukemia, Myeloid, Acute +[4] 
Inactive IndicationsN/A

Other Information

ATC CodeN/A
Related LinksN/A